Capital Fund Management S.A. Increases Stock Position in RELX PLC $RELX

Key Points

• Capital Fund Management S.A. increased its stake in Relx Plc by 129.3% during the 1st quarter, acquiring an additional 26,558 shares to reach a total of 47,103 shares.
• Relx has declared a semi-annual dividend of $0.2634, scheduled for payment on September 16th, with a dividend yield of 170.0%.
• Analysts have upgraded Relx from a "hold" to a "buy" rating, with strong interest shown by institutional investors, who own 15.02% of the company's stock.

Capital Fund Management S.A. raised its position in shares of RELX PLC (NYSE:RELX - Free Report) by 129.3% in the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 47,103 shares of the technology company's stock after purchasing an additional 26,558 shares during the quarter. Capital Fund Management S.A.'s holdings in RELX were worth $2,374,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. ABC Arbitrage SA increased its position in shares of RELX by 40.1% during the first quarter. ABC Arbitrage SA now owns 194,197 shares of the technology company's stock valued at $9,789,000 after acquiring an additional 55,579 shares in the last quarter. Pandora Wealth Inc. bought a new stake in shares of RELX in the 1st quarter worth $757,000. Charles Schwab Investment Management Inc. raised its stake in shares of RELX by 16.5% in the first quarter. Charles Schwab Investment Management Inc. now owns 167,175 shares of the technology company's stock worth $8,427,000 after purchasing an additional 23,692 shares during the last quarter. Massachusetts Financial Services Co. MA lifted its holdings in shares of RELX by 103.7% during the first quarter. Massachusetts Financial Services Co. MA now owns 106,220 shares of the technology company's stock valued at $5,355,000 after purchasing an additional 54,062 shares in the last quarter. Finally, Cambridge Investment Research Advisors Inc. boosted its position in shares of RELX by 19.5% during the first quarter. Cambridge Investment Research Advisors Inc. now owns 18,957 shares of the technology company's stock valued at $956,000 after buying an additional 3,092 shares during the last quarter. Institutional investors own 15.02% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen raised RELX from a "hold" rating to a "buy" rating in a research report on Saturday, July 26th. One investment analyst has rated the stock with a Strong Buy rating and four have issued a Buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Buy".

RELX Stock Performance

Shares of RELX stock traded down $0.32 on Friday, hitting $46.64. 1,853,527 shares of the company's stock were exchanged, compared to its average volume of 1,586,397. The company has a debt-to-equity ratio of 2.55, a quick ratio of 0.42 and a current ratio of 0.47. The stock has a market capitalization of $85.56 billion, a PE ratio of 25.08, a PEG ratio of 3.04 and a beta of 0.88. RELX PLC has a 1 year low of $44.19 and a 1 year high of $56.33. The company has a 50-day simple moving average of $51.18 and a 200-day simple moving average of $51.38.

RELX Cuts Dividend

The company also recently declared a semi-annual dividend, which will be paid on Tuesday, September 16th. Shareholders of record on Friday, August 8th will be given a $0.2634 dividend. This represents a dividend yield of 170.0%. The ex-dividend date is Friday, August 8th. RELX's dividend payout ratio is presently 28.49%.

About RELX

RELX Plc engages in provision of information and analytics solutions for professional and business customers across industries. It operates through the following business segments: Scientific, Technical & Medical; Risk & Business Analytics; Legal; and Exhibitions. The Scientific, Technical & Medical segment is a global information analytics business that helps institutions and professionals advance healthcare, open science, and improve performance for the benefit of humanity.